EMA's Business Continuity Plan for Brexit published

16 October 2017

Plan aims to ensure continuity of Agency's operations

The European Medicines Agency (EMA) has published today its European Medicines Agency Brexit Preparedness Business Continuity Plan. The plan aims to safeguard continuity of EMA's operations to protect public health while the Agency prepares for its relocation to a new host city and the departure of the United Kingdom from the European Union (EU). The Business Continuity Plan was presented to the Management Board meeting in October 2017 in line with the principles and methodology that were endorsed by the board at its June 2017 meeting*.

It describes the methodology by which EMA has categorised and prioritised its activities and how it plans to reallocate resources to its core activities if needed. The plan prioritises tasks and activities and classifies them into three categories according to their impact on public health and the Agency's ability to function.

The plan will be continuously reviewed and adapted as necessary.

Note

^*Updated on 17 October 2017 to clarify that the principles and methodology were endorsed in June rather than the final plan.